NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









RAGE Biotech

RAGE Biotech

Private
MelbourneHealthcare & Life Scienceshttps://www.ragebiotech.com/

Last Round

Series A

Nov 13, 2025

Total Funding Raised

$24.17M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

RAGE Biotech is a biotechnology company developing novel therapeutics targeting the Receptor for Advanced Glycation End-products (RAGE) for patients with difficult-to-treat inflammatory disease.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Non-AI

Keywords

rna therapeuticssplice-switching oligonucleotideSSOdrug discoveryprecision medicinechronic inflammatory diseaseCOPD treatmentRAGE modulationbiotech startupinhaled therapeuticsfibrosis researchrna medicinedrug pipelinebiopharma partnershiprna drug platform

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

RAGE Biotech Comparables

Compare RAGE Biotech with similar companies based on industry and business-model similarity.

RAGE Biotech comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Cantex Pharmaceuticals
77%
Arrowhead Pharmaceuticals
76%
Ethris
72%

RAGE Biotech Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series ANov 13, 2025
GrantSep 4, 2025
GrantSep 4, 2024
AcceleratorApr 18, 2024
GrantDec 21, 2022
Grant
Jul 19, 2022

RAGE Biotech Investors

Notable investors and investment history

RAGE Biotech investors
InvestorRounds
IP GroupSeed
CUREatorGrant
Hostplus Superannuation FundSeries A
IP Group AustraliaSeries A
mRNA VictoriaGrant
Monash Investment HoldingsSeed, Series A
Jumar BioincubatorAccelerator

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 13, 2025

    $21M round completed.

RAGE Biotech Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

RAGE Biotech Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about RAGE Biotech's valuation, stock price, and market status.

Firmographic Details

HeadquartersMelbourne
Employee Range8
Year Founded2020
Last FundingNov 13, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.